Hyperfine, Inc. (HYPR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hyperfine, Inc. (HYPR) trades at $1.28 with AI Score 16/100 (Grade F). Hyperfine, Inc. specializes in portable magnetic resonance imaging, offering the Swoop system for point-of-care medical imaging. Market cap: $108.22M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for HYPR: HYPR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HYPR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HYPR: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Hyperfine, Inc. (HYPR) Healthcare & Pipeline Overview
Hyperfine, Inc. delivers point-of-care medical imaging solutions with its Swoop Portable MR imaging system. Targeting unmet needs in the healthcare sector, Hyperfine combines hardware and software to provide accessible and efficient imaging. The company operates in the medical devices industry with a focus on innovation and accessibility.
What Is the Investment Thesis for HYPR?
Hyperfine, Inc. presents a compelling investment thesis centered on its innovative Swoop Portable MR Imaging System. The company's focus on point-of-care imaging addresses a significant unmet need in the healthcare industry. Key value drivers include the expansion of Swoop's market reach, increased adoption by hospitals and medical facilities, and the development of new clinical applications. The company's gross margin of 49.8% indicates potential for profitability as sales scale. Upcoming catalysts include potential regulatory approvals for new features and applications of the Swoop system. However, potential risks include competition from established medical imaging companies and the need for continued innovation to maintain a competitive edge. Investors should monitor the company's ability to drive adoption of the Swoop system and manage its operating expenses to achieve sustainable growth.
Based on FMP financials and quantitative analysis
HYPR Key Highlights
- Market capitalization of $108.22M, reflecting investor valuation of the company's growth potential.
- Gross margin of 49.8%, indicating strong potential for profitability as sales increase.
- Beta of 1.06, suggesting the stock's volatility is similar to the overall market.
- Focus on point-of-care medical imaging with the Swoop Portable MR imaging system.
- Addresses unmet needs in medical imaging through innovative hardware and software services.
Who Are HYPR's Competitors?
HYPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GE GE Aerospace | $378.99 | +0.39% | $395.98B | 72 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| AXGN AxoGen, Inc. | $45.08 | -1.77% | $2.40B | 58 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HYPR's Key Strengths?
- Innovative Swoop Portable MR Imaging System.
- Focus on point-of-care medical imaging.
- Strong intellectual property portfolio.
- Potential for rapid growth in a niche market.
What Are HYPR's Weaknesses?
- Limited market presence compared to established competitors.
- Reliance on a single product line.
- Negative profit margin.
- Relatively small employee base.
What Could Drive HYPR Stock Higher?
- Potential regulatory approvals for new features and applications of the Swoop system.
- Expansion of Swoop's market reach through strategic partnerships.
- Increased adoption of Swoop by hospitals and medical facilities.
- Development of AI-powered solutions for enhanced diagnostic capabilities.
What Are the Key Risks for HYPR?
- Financial-distress signal — its Altman Z-Score of -6.06 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established medical imaging companies.
- Technological obsolescence requiring continuous innovation.
- Regulatory hurdles and compliance requirements.
- Economic downturns affecting healthcare spending.
- Reliance on a single product line.
What Are the Growth Opportunities for HYPR?
- Expansion into New Clinical Applications: Hyperfine has the opportunity to expand the clinical applications of its Swoop Portable MR Imaging System. By developing new software and hardware features, the company can target additional medical specialties and patient populations. The market for specialized medical imaging is estimated to reach $45 billion by 2030, presenting a significant growth opportunity for Hyperfine. Timeline: Ongoing.
- Geographic Expansion: Hyperfine can drive growth by expanding its geographic presence. The company's Swoop system has the potential to address unmet needs in international markets, particularly in developing countries with limited access to traditional MRI technology. The global market for portable medical devices is projected to reach $25 billion by 2028. Timeline: Next 3-5 years.
- Strategic Partnerships: Forming strategic partnerships with hospitals, medical centers, and research institutions can accelerate the adoption of Hyperfine's Swoop system. Collaborations can provide access to new markets, enhance product development, and strengthen the company's competitive position. The market for healthcare partnerships is growing at a rate of 8% annually. Timeline: Ongoing.
- Development of AI-Powered Solutions: Integrating artificial intelligence (AI) into the Swoop system can enhance its diagnostic capabilities and improve workflow efficiency. AI algorithms can be used to automate image analysis, detect anomalies, and provide decision support to clinicians. The market for AI in healthcare is projected to reach $67 billion by 2027. Timeline: Next 2-3 years.
- Subscription-Based Service Model: Hyperfine can transition to a subscription-based service model, offering the Swoop system and associated services for a recurring fee. This model can provide a predictable revenue stream, enhance customer loyalty, and drive long-term growth. The market for subscription-based healthcare services is growing at a rate of 12% annually. Timeline: Next 1-2 years.
What Opportunities Does HYPR Have?
- Expansion into new clinical applications.
- Geographic expansion into international markets.
- Strategic partnerships with hospitals and research institutions.
- Integration of AI-powered solutions.
What Threats Does HYPR Face?
- Competition from established medical imaging companies.
- Technological obsolescence.
- Regulatory hurdles.
- Economic downturns affecting healthcare spending.
What Are HYPR's Competitive Advantages?
- Proprietary technology in portable MRI systems.
- First-mover advantage in the point-of-care imaging market.
- Strong intellectual property portfolio.
- Established relationships with key customers.
What Does HYPR Do?
Hyperfine, Inc., founded in 2014 and based in Guilford, Connecticut, is a medical device company focused on revolutionizing magnetic resonance imaging (MRI). The company's core product is the Swoop Portable MR Imaging System, designed to address the limitations of traditional MRI systems by providing a portable, accessible, and cost-effective imaging solution. Swoop aims to bring MRI capabilities directly to the patient's bedside, enabling faster diagnosis and treatment in various clinical settings. Hyperfine's business model centers on the development, manufacturing, and commercialization of its Swoop system, along with associated hardware and software services. The company targets hospitals, emergency rooms, intensive care units, and other point-of-care locations. Hyperfine's technology seeks to overcome the challenges of traditional MRI, such as high costs, infrastructure requirements, and patient transport limitations. By offering a portable and user-friendly MRI system, Hyperfine aims to expand the reach of medical imaging and improve patient outcomes.
What Products and Services Does HYPR Offer?
- Develop and manufacture the Swoop Portable MR Imaging System.
- Provide point-of-care medical imaging solutions.
- Offer hardware and software services for medical imaging.
- Address unmet needs in the healthcare industry.
- Enable faster diagnosis and treatment in clinical settings.
- Focus on portability and accessibility of MRI technology.
How Does HYPR Make Money?
- Sales of the Swoop Portable MR Imaging System.
- Revenue from associated hardware and software services.
- Potential for subscription-based service model.
- Targeting hospitals, emergency rooms, and intensive care units.
What Industry Does HYPR Operate In?
Hyperfine, Inc. operates in the medical devices industry, which is characterized by rapid technological advancements and increasing demand for innovative healthcare solutions. The market for medical imaging is substantial, driven by the growing prevalence of chronic diseases and the need for early and accurate diagnosis. Hyperfine's focus on portable MRI systems positions it within a niche segment of the market, offering a unique value proposition compared to traditional MRI systems. Key competitors include established medical imaging companies with broader product portfolios. The industry is subject to regulatory oversight and requires ongoing investment in research and development to maintain a competitive edge.
Who Are HYPR's Key Customers?
- Hospitals and medical centers.
- Emergency rooms and intensive care units.
- Research institutions.
- Clinicians and medical professionals.
FY2026 estForward Outlook
Wall Street analysts project Hyperfine, Inc. revenue of about $20.2M for fiscal 2026, with EPS near $-0.35.
HYPR Valuation & Market Position
With a $108.22M market cap, Hyperfine, Inc. sits in the micro-cap segment of the market. Relative to its peer group, HYPR's quantitative score of 16/100 is below the peer average of 72/100.
Key Financial Metrics
Return on assets is -57.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Hyperfine, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.06 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Hyperfine, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Guilford, US. The company is led by CEO Maria Degois-Sainz. HYPR has traded publicly since 2021.
HYPR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in the company's future prospects, suggesting that executives believe in the value of their innovations.
- Community sentiment has shifted positively, with increased discussions around the potential of Hyperfine's portable MRI technology, capturing interest from both investors and healthcare professionals.
- Market perception is bolstered by recent partnerships that could expand the reach of their technology, enhancing credibility and potential revenue streams.
- The growing demand for accessible medical imaging solutions aligns well with Hyperfine's mission, positioning the company favorably in a rapidly evolving healthcare landscape.
Bear Case
- Concerns about the scalability of Hyperfine's technology persist, as some investors question whether the current infrastructure can support widespread adoption.
- Recent bearish sentiment in social trading forums highlights skepticism about the company's ability to compete against established players in the medical imaging industry.
- Insider selling activity has raised red flags for some investors, leading to fears about the long-term commitment of key executives to the company's vision.
- Ongoing regulatory challenges in the healthcare sector could pose significant hurdles for Hyperfine, potentially delaying product rollouts and impacting market confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HYPR Latest News
-
Hyperfine, Forward Industries, Sharplink Set for Russell Index Inclusion
MT Newswires · May 26, 2026
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
-
Earnings Scheduled For August 13, 2025
benzinga · Aug 13, 2025
HYPR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HYPR.
Price Targets
Wall Street price target analysis for HYPR.
HYPR MoonshotScore
What does this score mean?
The MoonshotScore rates HYPR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Maria Degois-Sainz
CEO
Maria Degois-Sainz serves as the CEO of Hyperfine, Inc., bringing extensive experience in the medical device industry. Her background includes leadership roles in product development, commercialization, and strategic planning. Prior to joining Hyperfine, she held key positions at leading healthcare companies, where she focused on driving innovation and expanding market access for medical technologies. Her expertise spans various therapeutic areas, including imaging, diagnostics, and interventional procedures. She is known for her ability to build high-performing teams and execute strategic initiatives.
Track Record: Under Maria Degois-Sainz's leadership, Hyperfine has focused on expanding the market reach of its Swoop Portable MR Imaging System and driving adoption by hospitals and medical facilities. She has overseen the development of new clinical applications for the Swoop system and has led efforts to secure regulatory approvals. Her strategic decisions have positioned Hyperfine as a key player in the point-of-care imaging market.
What Investors Ask About Hyperfine, Inc. (HYPR) — Healthcare
What does Hyperfine, Inc. do?
Hyperfine, Inc. is a medical device company specializing in point-of-care magnetic resonance imaging (MRI). Its primary product, the Swoop Portable MR Imaging System, is designed to provide accessible and efficient imaging at the patient's bedside. This technology addresses the limitations of traditional MRI systems, such as high costs and infrastructure requirements, by offering a portable and user-friendly solution. Hyperfine aims to improve patient outcomes by enabling faster diagnosis and treatment in various clinical settings, including hospitals, emergency rooms, and intensive care units.
What do analysts say about HYPR stock?
Analyst coverage of Hyperfine, Inc. (HYPR) focuses on the company's growth potential in the point-of-care medical imaging market. Key valuation metrics include market capitalization and revenue growth. Analysts monitor the company's ability to drive adoption of the Swoop system and manage its operating expenses. Consensus estimates suggest continued revenue growth driven by expansion into new clinical applications and geographic markets. However, analysts also highlight the risks associated with competition from established medical imaging companies and the need for ongoing innovation to maintain a competitive edge. No buy or sell recommendations are made.
What are the main risks for HYPR?
Hyperfine, Inc. faces several risks, including competition from larger, more established medical imaging companies with greater resources. Technological obsolescence is a concern, requiring continuous investment in research and development to maintain a competitive edge. Regulatory hurdles and compliance requirements can impact the company's ability to bring new products to market. Economic downturns affecting healthcare spending could reduce demand for Hyperfine's products. The company's reliance on a single product line also poses a risk, as any issues with the Swoop system could significantly impact its financial performance.
What are the key factors to evaluate for HYPR?
Hyperfine, Inc. (HYPR) holds an AI score of 16/100 (low). Not financial advice.
How frequently does HYPR data refresh on this page?
HYPR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HYPR's recent stock price performance?
Hyperfine, Inc. (HYPR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Swoop Portable MR Imaging System. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HYPR overvalued or undervalued right now?
Valuing Hyperfine, Inc. (HYPR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HYPR?
Before investing in Hyperfine, Inc. (HYPR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest reporting period.